博瑞医药：关于放弃对参股公司增资扩股优先认购权暨关联交易的公告

Core Viewpoint - 博瑞医药's subsidiary, Shenzhen Aoli Biotechnology Co., Ltd., is planning a capital increase, with total investments amounting to RMB 8 million, leading to a dilution of 博瑞医药's ownership stake from 30.1664% to 24.420458% [2] Group 1 - 博瑞医药 announced that its subsidiary, Aoli Biotechnology, will undergo a capital increase [2] - Suzhou Hongbo Phase II Investment Partnership is set to invest RMB 25 million, while other investors will contribute RMB 55 million [2] - 博瑞医药 has chosen to waive its preemptive rights regarding this capital increase [2] Group 2 - Following the capital increase, 博瑞医药's ownership in Aoli Biotechnology will decrease significantly [2] - The transaction has been approved by 博瑞医药's board of directors and does not require shareholder approval [2] - The controlling shareholder, 袁建栋, is involved in the investment decision-making process, indicating a related party transaction [2]